|
gptkbp:instanceOf
|
direct thrombin inhibitor
anticoagulant drug
|
|
gptkbp:antidote
|
gptkb:idarucizumab
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
6.5%
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:CASNumber
|
211914-51-1
|
|
gptkbp:contraindication
|
active pathological bleeding
|
|
gptkbp:developer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:drugClass
|
NOAC (novel oral anticoagulant)
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasBoxedWarning
|
risk of spinal/epidural hematoma
increased risk of thrombotic events if discontinued prematurely
|
|
gptkbp:hasMolecularFormula
|
C34H41N7O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dabigatran
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits thrombin (factor IIa)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:riskFactor
|
increased risk of bleeding with other anticoagulants
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
gastrointestinal upset
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:bfsParent
|
gptkb:DB09054
gptkb:DB12023
|
|
gptkbp:bfsLayer
|
6
|